| 24.27 -1.23 (-4.82%) | 03-30 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 31.89  |
1-year : | 39.7 |
| Resists | First : | 27.3 |
Second : | 33.99 |
| Pivot price | 23.96 |
|||
| Supports | First : | 16.5 |
Second : | 13.72 |
| MAs | MA(5) : | 24.87  |
MA(20) : | 25.15 |
| MA(100) : | 24.41 |
MA(250) : | 0 | |
| MACD | MACD : | -0.9 |
Signal : | -1 |
| %K %D | K(14,3) : | 63.8 |
D(3) : | 62.1 |
| RSI | RSI(14): 47 |
|||
| 52-week | High : | 38.32 | Low : | 2 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ DMRA ] has closed below upper band by 46.9%. Bollinger Bands are 29.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 26.2 - 26.34 | 26.34 - 26.46 |
| Low: | 23.44 - 23.6 | 23.6 - 23.74 |
| Close: | 24.02 - 24.27 | 24.27 - 24.49 |
Galecto, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The firm is also involved in the development of small molecule inhibitors of galectin-3 and LOXL2. The company was founded by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye in 2011 and is headquartered in Boston, MA.
Fri, 27 Mar 2026
Damora Therapeutics Inc (DMRA) Stock Earnings Transcripts - GuruFocus
Wed, 25 Mar 2026
Damora Therapeutics (DMRA) grants 250,000 stock options to General Counsel - Stock Titan
Wed, 25 Mar 2026
Damora Therapeutics director granted 37,313 options | DMRA Insider Trading - Stock Titan
Wed, 25 Mar 2026
Damora Therapeutics (DMRA) director receives 37,313-share stock option grant - Stock Titan
Wed, 25 Mar 2026
Damora Therapeutics (DMRA) insiders receive 37,313-share option grant via Fairmount - Stock Titan
Wed, 25 Mar 2026
Damora Therapeutics (DMRA) director option grant tied to Fairmount funds - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Pharmaceuticals
|
|
| Shares Out | 60 (M) |
| Shares Float | 48 (M) |
| Held by Insiders | 1.4 (%) |
| Held by Institutions | 7.9 (%) |
| Shares Short | 428 (K) |
| Shares Short P.Month | 148 (K) |
| EPS | -3.99 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -110.12 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -16.5 % |
| Return on Equity (ttm) | -163.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.61 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -7 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -6.1 |
| PEG Ratio | 0 |
| Price to Book value | -0.23 |
| Price to Sales | 0 |
| Price to Cash Flow | -217.46 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|